Truist Securities Downgrades Gilead Sciences to Hold, Lowers Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas downgraded Gilead Sciences (GILD) from Buy to Hold and reduced the price target from $91 to $82.
February 22, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities downgraded Gilead Sciences from Buy to Hold and lowered the price target from $91 to $82.
Analyst downgrades typically lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The reduction in the price target further emphasizes a less optimistic outlook on the company's valuation, likely influencing investor sentiment negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100